Marc Semigran - 03 Sep 2021 Form 4 Insider Report for Renovacor, Inc.

Role
Chief Medical Officer
Signature
/s/ Joseph Carroll, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Sep 2021
Net transactions value
$0
Form type
4
Filing time
08 Sep 2021, 18:59:16 UTC
Previous filing
07 Sep 2021
Next filing
22 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCOR Option Award $0 +169,849 $0.000000 169,849 03 Sep 2021 Common Stock 169,849 $7.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest and become exercisable in full on September 3, 2025, with 25% vesting on September 3, 2022, and the remainder vesting in equal monthly installments on the 3rd of each month for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date.